Everolimus after failure of one prior VEGF‐targeted therapy in metastatic renal cell carcinoma: Final results of the MARC‐2 trial
Authors:
- Michael StaehlerMichael Staehler
- Michael StöckleMSMichael Stöckle
- Daniel C. ChristophDCDaniel C. Christoph
- Arnulf StenzlASArnulf Stenzl
- Karin PotthoffKPKarin Potthoff
- Marc‐Oliver GrimmMGMarc‐Oliver Grimm
- Dunja KleinDKDunja Klein
- Johanna HardeJHJohanna Harde
- Fabian BrüningFBFabian Brüning
- Peter J. GoebellPGPeter J. Goebell
- Marinela AugustinMAMarinela Augustin
- Frederik RoosFRFrederik Roos
Open Access
- 18 October 2020
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 148 (7) , 1685-1694
Abstract
MARC‐2, a prospective, multicenter phase IV trial, aimed to investigate clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of one initial vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR‐TKI) therapy and to identify subgroups benefiting most, based on clinical characteristics and biomarkers. Patients with clear cell mRCC failing one initial VEGFR‐TKI received everolimus until progression or unacceptable toxicity. Primary endpoint was 6‐month progression‐free survival rate (6moPFS). Secondary endpoints were overall response rate (ORR), PFS, overall survival (OS), and safety. Between 2011 and 2015, 63 patients were enrolled. Median age was 65.4 years (range 43.3‐81.1). 6moPFS was 39.3% (95% confidence interval [CI], 27.0‐51.3) overall, 54.4% (95% CI, 35.2‐70.1) vs 23.7% (95% CI, 10.5‐39.9) for patients aged ≥65 vs 25 vs ≤25 kg/m2. A Cox proportional hazards model confirmed a longer PFS for patients aged ≥65 years (hazard ratio [HR] 0.46; 95% CI, 0.26‐0.80) and a longer OS for patients with BMI >25 kg/m2 (HR 0.36; 95% CI, 0.18‐0.71). Median PFS and median OS were 3.8 months (95% CI, 3.2‐6.2) and 16.8 months (95% CI, 14.3‐24.3). ORR was 7.9% and disease control rate was 60.3%. No new safety signals emerged. Most common adverse events were stomatitis (31.7%), fatigue (31.7%), and anemia (30.2%). One patient died from treatment‐related upper gastrointestinal hemorrhage. Everolimus remains a safe and effective treatment option for mRCC patients after one prior VEGFR‐TKI therapy. Patients aged ≥65 years and patients with BMI >25 kg/m2 benefited most.Keywords
Funding Information
- Novartis Pharma (CRAD001LDE36T)
This publication has 25 references indexed in Scilit:
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trialThe Lancet, 2019
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2019
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2019
- Personalized Management of Advanced Kidney CancerAmerican Society of Clinical Oncology Educational Book, 2018
- Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapiesUrologic Oncology: Seminars and Original Investigations, 2016
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trialThe Lancet Oncology, 2015
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Sunitinib Efficacy Against Advanced Renal Cell CarcinomaJournal of Urology, 2007